10 April 2019PatentsClaire Irvine

Life sciences: It pays to be wary over CRISPR

Given recent decisions, one might be forgiven for thinking that clarity is fast approaching in the CRISPR IP world. Far from it.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

Tourism’s influence on defining the ‘relevant public’ in EUTM oppositions

‘Trade secrets can be emotional’: Seth Gerber, Morgan Lewis

Private equity eyes controlling interest in Anaqua

Motorola can’t enforce ‘multiple’ US Hytera damages in UK

UK firms Venner Shipley and AA Thornton combine

Kathi Vidal to rejoin previous firm as partner following USPTO departure

Around the world with trade secrets

Brown Rudnick hires eight-person team from Bochner

Life sciences: It pays to be wary over CRISPR

Editor's picks

Editor's picks

More articles